TrialCancer2018

Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

Rita Assi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.